Insights

Stay Informed, Stay Ahead: CVS’s Transition from Humira to Biosimilars

Earlier this month, CVS announced a major change to some of their formularies. This includes the removal of Humira, a widely used medication.
Learn More

Spotlight: Featured on Self-Funded with Spencer Podcast

Brian Shonat, Goodroot’s area vice president of business development, recently joined Spencer Smith on the Self-Funded with Spencer podcast
Learn More

Levemir Discontinuation: What You Need to Know

Important update regarding a recent development about Novo Nordisk’s announcement to discontinue Levemir.
Learn More

Beyond Unit Cost: Evaluating Clinical Programs and Capabilities of PBMs

Here are three major factors brokers and employer groups should consider beyond unit cost when choosing a PBM.
Learn More

Medicaid AMP Cap Removal: Market Changes & Rx Strategies Amidst New Provisions

This article dives deep into these shifts and the subsequent reactions from industry stakeholders.
Learn More

AlignRx President & CEO Kevin Kobielski Recognized in 2023 BenefitsPRO Luminaries Awards

BenefitsPRO, the No.1 provider of news, analysis and trends for benefits professionals, has announced its 2023 Luminaries Awards recognizing excellence in the benefits industry.
Learn More

AlignRx Consulting Recognized on the 2023 Inc. 5000 List of Fastest Growing Companies

Inc. revealed today that AlignRx Consulting ranks No. 898 on the 2023 Inc. 5000, its annual list of the fastest-growing private companies in America.
Learn More

Filter Insights:

Join our newsletter to stay up to date on market trends.

By subscribing you agree to with our Privacy Policy and provide consent to receive updates from our company.

Latest Clinical Insight

AlignRx Consulting Rebrands as Navion, Continues to Elevate Pharmacy Benefits Solutions to New Heights 

AlignRx Consulting, a leader in the pharmacy benefit consulting space, is rebranding as Navion, reflecting the company’s evolution in delivering industry-leading pharmacy benefit solutions.